Last reviewed · How we verify
Intravitreal aflibercept injection 2.0mg
Intravitreal aflibercept injection 2.0mg is a Small molecule drug developed by Gregg T. Kokame, MD. It is currently FDA-approved. Also known as: Eylea.
At a glance
| Generic name | Intravitreal aflibercept injection 2.0mg |
|---|---|
| Also known as | Eylea |
| Sponsor | Gregg T. Kokame, MD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy (PHASE4)
- A Study of Longer Interval of IVT IBI302 in Subjects With nAMD (PHASE2)
- Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion (PHASE4)
- Aflibercept Injection for Proliferative Diabetic Retinopathy (PHASE2)
- Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema (PHASE3)
- Efficacy and Safety of RC28-E Versus Aflibercept (PHASE3)
- A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema. (PHASE2)
- Anti-VEGF Treatment for Prevention of PDR/DME (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal aflibercept injection 2.0mg CI brief — competitive landscape report
- Intravitreal aflibercept injection 2.0mg updates RSS · CI watch RSS
- Gregg T. Kokame, MD portfolio CI
Frequently asked questions about Intravitreal aflibercept injection 2.0mg
What is Intravitreal aflibercept injection 2.0mg?
Intravitreal aflibercept injection 2.0mg is a Small molecule drug developed by Gregg T. Kokame, MD.
Who makes Intravitreal aflibercept injection 2.0mg?
Intravitreal aflibercept injection 2.0mg is developed and marketed by Gregg T. Kokame, MD (see full Gregg T. Kokame, MD pipeline at /company/gregg-t-kokame-md).
Is Intravitreal aflibercept injection 2.0mg also known as anything else?
Intravitreal aflibercept injection 2.0mg is also known as Eylea.
What development phase is Intravitreal aflibercept injection 2.0mg in?
Intravitreal aflibercept injection 2.0mg is FDA-approved (marketed).
Related
- Manufacturer: Gregg T. Kokame, MD — full pipeline
- Also known as: Eylea
- Compare: Intravitreal aflibercept injection 2.0mg vs similar drugs
- Pricing: Intravitreal aflibercept injection 2.0mg cost, discount & access